gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SPRYHealthcarePharmaceuticals

ARS Pharmaceuticals, Inc. Common Stock (SPRY)

$3.050.00%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$3.05▼ 64.62% in range
Nov 3, 2025Low $3.05 · High $13.06Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

ARS Pharmaceuticals closed at $3.05 on Nov 4, unchanged, within 0.0% of its 52-week closing low. Volume of 2.5M shares was 1.44× its 20-day average (above normal).

Split-adjusted performance: -29.0% over one month, -67.1% over six months, -64.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $33.66M, up 114.2% from a year earlier, with a net margin of -185.2%.

Short interest was 19.8M shares at the Oct 15 settlement, down 6.5% from the prior report (40.5% of float, 12.6 days to cover).

Market cap$303.3M99.4M shares
Revenue · quarter$33.7M+114.2% YoY
Diluted EPS$-0.63—
P/E · TTM—P/S 2.6×
Net margin-185.2%Gross 61.8%
Dividend yieldNone
52-week range3.05 – 13.06−76.6% from high
Volume2.5M1.44× 20-day avg
Volatility · 60d69.9%Annualised
Short % of float40.5%12.6 days to cover
Net cash-$27.8MCash $143.8M
Next earnings—Not scheduled
Split-adjusted performance
1W −16.4%1M −29.0%3M −45.0%6M −67.1%YTD −73.8%1Y −64.6%3Y −12.4%5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum14
Revenue growth85
Net margin39
Value (low P/E)—
Size54

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short19.8M−6.5% vs prior
Days to cover12.6Settled Oct 15
% of float40.5%
Short vol. 10d50.6%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SPRYARS Pharmaceuticals$3.050.00%−67.1%+114.2%−185.2%—$303.3M
EBSEmergent Biosolutions$5.90−5.60%−35.2%−52.4%−29.7%—$302.5MCompare
ARCTArcturus Therapeutics Holdings$10.87+13.94%+19.1%−89.5%−803.8%—$309.0MCompare
TTRXTurn Therapeutics$9.80+3.05%+158.2%———$297.6MCompare
CYPHCypherpunk Technologies$2.87+10.38%+154.0%———$309.3MCompare
ENTAEnanta Pharmaceuticals$10.65+2.70%−30.1%−21.6%−135.8%—$310.2MCompare
VOGXVogenx$19.73−3.90%————$293.1MCompare
CGCCanopy Growth$0.7517+6.37%−34.6%+7.8%−18.0%—$318.0MCompare
FULCFulcrum Therapeutics$3.77+0.80%−47.0%———$288.0MCompare

News about ARS Pharmaceuticals

All news →
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research · 6d ago▼ NegativeARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYGlobeNewswire Inc. · Oct 2, 2026▼ NegativeARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff RoleGlobeNewswire Inc. · Oct 2, 2026▼ NegativeARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRYGlobeNewswire Inc. · Sep 29, 2026▼ NegativeSPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS LawGlobeNewswire Inc. · Sep 24, 2026▼ Negative

Quick answers

What does ARS Pharmaceuticals do?
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
What is SPRY's market cap?
$303.31M, based on the Nov 4 close of $3.05.
Does ARS Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SPRY is sold short?
19.8M shares, 40.5% of float, as of Oct 15, 2026.
What sector is SPRY in?
Healthcare, in the Pharmaceuticals industry.

About ARS Pharmaceuticals

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

HQ: San Diego, CA200 employeesListed Nov 9, 2022ars-pharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology